Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aceclofenac + paracetamol + serratiopeptidase (Zinnia Life Sciences)
- Development stage
- Unknown
- Lead developer
- Zinnia Life Sciences
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Zinidol-SP is a fixed-dose combination oral tablet containing the non-steroidal anti-inflammatory drug (NSAID) aceclofenac, the analgesic and antipyretic paracetamol, and the proteolytic enzyme serratiopeptidase. Developed by Zinnia Life Sciences, it is indicated for the relief of severe pain, swelling, and inflammation associated with musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, as well as post-operative inflammation and dental pain. Aceclofenac and paracetamol work synergistically to inhibit prostaglandin synthesis via cyclooxygenase (COX) pathway blockade, while serratiopeptidase promotes the breakdown of fibrin and reduces fluid viscosity at inflammatory sites to facilitate drainage and alleviate edema.
- Brand names
- Zinidol-SP
- Other names
- Aceclofenac, Paracetamol & Serratiopeptidase TabletsZinidol SP
02
Targets
BK (Bradykinin)Fibrin (Factor Ia)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on aceclofenac + paracetamol + serratiopeptidase (Zinnia Life Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aceclofenac + paracetamol + serratiopeptidase (Zinnia Life Sciences).